{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:26:42Z","timestamp":1787135202499,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06695-5","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:50:38Z","timestamp":1787133038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis"],"prefix":"10.1007","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct02489318","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tomohiro","family":"Hori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Kamijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Kadomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"1","key":"6695_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"6695_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 377(4):352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"issue":"1","key":"6695_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"},{"issue":"12","key":"6695_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F et al (2022) Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386(12):1132\u20131142. https:\/\/doi.org\/10.1056\/NEJMoa2119115","journal-title":"N Engl J Med"},{"issue":"2","key":"6695_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 381(2):121\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1903835","journal-title":"N Engl J Med"},{"issue":"32","key":"6695_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP et al (2019) ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 37(32):2974\u20132986. https:\/\/doi.org\/10.1200\/JCO.19.00799","journal-title":"J Clin Oncol"},{"issue":"10","key":"6695_CR7","doi-asserted-by":"publisher","first-page":"e2336604","DOI":"10.1001\/jamanetworkopen.2023.36604","volume":"6","author":"C Corsini","year":"2023","unstructured":"Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M (2023) Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. JAMA Netw Open 6(10):e2336604 Published 2023 Oct 2. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36604","journal-title":"JAMA Netw Open"},{"issue":"9","key":"6695_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","volume":"28","author":"PC Barata","year":"2023","unstructured":"Barata PC, Leith A, Ribbands A et al (2023) Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study. Oncologist 28(9):780\u2013789. https:\/\/doi.org\/10.1093\/oncolo\/oyad045","journal-title":"Oncologist"},{"issue":"4","key":"6695_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.euo.2023.11.013","volume":"7","author":"NJ Sathianathen","year":"2024","unstructured":"Sathianathen NJ, Lawrentschuk N, Konety B et al (2024) Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective? Eur Urol Oncol 7(4):870\u2013876. https:\/\/doi.org\/10.1016\/j.euo.2023.11.013","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"6695_CR10","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","volume":"10","author":"O El-Taji","year":"2024","unstructured":"El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A (2024) Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. JAMA Oncol 10(7):874\u2013884. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1549","journal-title":"JAMA Oncol"},{"issue":"18","key":"6695_CR11","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3390\/cancers16183198","volume":"16","author":"H Iwamoto","year":"2024","unstructured":"Iwamoto H, Hori T, Nakagawa R et al (2024) Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer. Cancers (Basel). ;16(18):3198. Published 2024 Sep 19. https:\/\/doi.org\/10.3390\/cancers16183198","journal-title":"Cancers (Basel)"},{"key":"6695_CR12","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 2.2026. (2026) ; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"8","key":"6695_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373(8):737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"issue":"5","key":"6695_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11523-018-0588-8","volume":"13","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Mosillo C et al (2018) Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. Target Oncol 13(5):649\u2013655. https:\/\/doi.org\/10.1007\/s11523-018-0588-8","journal-title":"Target Oncol"},{"issue":"20","key":"6695_CR15","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 39(20):2294\u20132303. https:\/\/doi.org\/10.1200\/JCO.20.03488","journal-title":"J Clin Oncol"},{"issue":"1","key":"6695_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, B\u00fchlmann P (2012) MissForest\u2013non-parametric missing value imputation for mixed-type data. Bioinformatics 28(1):112\u2013118. https:\/\/doi.org\/10.1093\/bioinformatics\/btr597","journal-title":"Bioinformatics"},{"issue":"4","key":"6695_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/sim.6370","volume":"34","author":"L Kang","year":"2015","unstructured":"Kang L, Chen W, Petrick NA, Gallas BD (2015) Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med 34(4):685\u2013703. https:\/\/doi.org\/10.1002\/sim.6370","journal-title":"Stat Med"},{"issue":"9","key":"6695_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1200\/JCO.23.01535","volume":"42","author":"S Halabi","year":"2024","unstructured":"Halabi S, Roy A, Rydzewska L et al (2024) Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 42(9):1044\u20131054. https:\/\/doi.org\/10.1200\/JCO.23.01535","journal-title":"J Clin Oncol"},{"key":"6695_CR19","doi-asserted-by":"publisher","first-page":"113290","DOI":"10.1016\/j.ejca.2023.113290","volume":"193","author":"AS Merseburger","year":"2023","unstructured":"Merseburger AS, Agarwal N, Bhaumik A et al (2023) Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. Eur J Cancer 193:113290. https:\/\/doi.org\/10.1016\/j.ejca.2023.113290","journal-title":"Eur J Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06695-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:50:39Z","timestamp":1787133039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06695-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6695"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06695-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tomohiro Hori certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment\/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are as follows: Ryunosuke Nakagawa received speaker honoraria from Ono Pharmaceutical. Renato Naito received speaker honoraria from Ono Pharmaceutical, MSD, Janssen, Nihon Medi-Physics, and Ethicon. Hiroaki Iwamoto received speaker honoraria from Janssen. Takahiro Nohara received speaker honoraria from Sysmex. Kouji Izumi has participated in clinical trials sponsored by AstraZeneca, MSD, Janssen, Bayer, Novartis, and Pfizer; received speaker honoraria from AstraZeneca, Janssen, Bayer, Novartis, Astellas, and Sysmex; received grants, research funding, and consulting fees from Janssen. Atsushi Mizokami has participated in clinical trials sponsored by Pfizer and AstraZeneca and received speaker honoraria from Astellas, AstraZeneca, Bayer, Janssen, PDR Pharma, Johnson & Johnson, and Sanofi. The other authors declare no conflicts of interest associated with this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Review boards at all participating institutions approved the trial, which was conducted in accordance with current International Conference on Harmonisation guidelines for Good Clinical Practice and according to Declaration of Helsinki principles. All the patients provided written informed consent.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"585"}}